SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2021 / Volume: 3 Issue: 4

Langerhans Cell Histiocytosis In Bone: A Case Report

Orkide Kutlu(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL OKMEYDANI SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-4402-2231
Gizem Meral(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL OKMEYDANI SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0001-9327-899X
Hasan Eruzun(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL OKMEYDANI SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-0355-1820
Özlem Buluz(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL OKMEYDANI SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-0273-9605
Ayça Zeynep Kutlu(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ)0000-0003-4561-3786
Suat Erol Çelik(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL OKMEYDANI SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-3825-9854
Pages
—
Publication Date
2021-10-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we reported a LCH patient with a malignant shaped lytic lesion in the thoracic spine and adjacent bone.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Langerhans cell histiocytosis (LCH) is a rare disease in which histiocytic infiltrations can be seen in bone, skin, lymph nodes, lungs, liver, spleen, bone marrow, central nervous system and endocrine glands.
📊
Key Findings & Data:In histology, Langerhans cells that do not contain phagocytic material in their cytoplasm, have a folded "coffee bean" appearance in their nucleus, express histiocyte markers CD1a, S100 and C207 and contain Birbeck granules under electron microscope.
💡
Conclusion & Impact:Here, we reported a LCH patient with a malignant shaped lytic lesion in the thoracic spine and adjacent bone.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:Langerhans Cell Histiocytosis · Histiocytosis In Bone · Histiocytosis

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease in which histiocytic infiltrations can be seen in bone, skin, lymph nodes, lungs, liver, spleen, bone marrow, central nervous system and endocrine glands. Pulmonary LCH has been closely associated with smoking while there is no data on genetic, viral or neoplastic etiology. In LCH with multiple system involvement, unifocal/multifocal infiltrations occur in two or more organs together with systemic symptoms such as weight loss and fever. In histology, Langerhans cells that do not contain phagocytic material in their cytoplasm, have a folded "coffee bean" appearance in their nucleus, express histiocyte markers CD1a, S100 and C207 and contain Birbeck granules under electron microscope. In treatment, if there is a risk of collapse in spinal or femoral bone lesions, surgery and radiotherapy can be applied for stabilization; if necessary, chemotherapy can be applied in multisystem disease. Here, we reported a LCH patient with a malignant shaped lytic lesion in the thoracic spine and adjacent bone.

🔖

Cite This Article

Kutlu, O., Meral, G., Eruzun, H., Buluz, Ö., Kutlu, A. Z., Çelik, S. E. (2021). Langerhans Cell Histiocytosis In Bone: A Case Report. Turkish Journal of Internal Medicine, Volume: 3 Issue: 4. https://doi.org/10.46310/tjim.876279

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. De Young B, Egeler RM, Rollins BJ. Langerhanscellhistiocytosis. In: WHO Classification of Tumours of SoftTissueand Bone, 4th ed, Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F (Eds), International AgencyforResearch on Cancer, Lyons 2013. p.356
  2. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patientswithLangerhanscellhistiocytosis. PLoSMed 2007; 4:e253.
  3. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursorversusdifferentiateddendriticcellsdefinesclinicallydistinct LCH risk groups. J ExpMed 2014; 211:669.
  4. Minkov M, Pötschger U, Grois N, et al. Bone marrowassessment in Langerhanscellhistiocytosis. Pediatr Blood Cancer 2007; 49:694.
  5. Götz G, Fichter J. Langerhans'-cellhistiocytosis in 58 adults. Eur J MedRes. 2004;9(11):510.
  6. Huang W, Yang X, Cao D, Xiao J, Yang M, Feng D, Huang Q, Wu Z, Zheng W, Jia L, WuS Eosinophilicgranuloma of spine in adults: a report of 30 cases and outcome.ActaNeurochir (Wien)2010;152(7):112.
  7. Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cel lhistiocytosis. Pediatr Blood Cancer 2009; 52:97.
  8. Badalian‐Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919‐1923.
  9. Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment. Cancer Sci. 2018;109(12):3707-3713.
  10. Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261‐272.
  11. Héritier S, Hélias‐Rodzewicz Z, Lapillonne H, et al. Circulating cell‐free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol. 2017;178(3):457‐ 467.
  12. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015; 126:26.
  13. Haroche J, Cohen‐Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim‐Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495‐1500.
  14. Diamond EL, Subbiah V, Lockhart AC, et al. Histiocytosis: analysis of data from the histology‐independent, phase 2, open‐label VE‐BASKET Study. JAMA Oncol. 2018;4:384‐ 388.
  15. Papapanagiotou M, Griewank KG, Hillen U, et al. Trametinib‐induced remission of an MEK1‐mutated langerhans cell histiocytosis. JCO Precis Oncol. 2017;1:1‐5.